Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Decoy Therapeutics laid out a refined corporate strategy to build a single pan-filovirus antiviral through the FDA Animal Rule pathway, with the program to be funded primarily through non-dilutive government grants and public health partnerships. In cell-based assays, its first-generation de novo candidate showed low-micromolar potency against wild-type Ebola Zaire — a 7-fold improvement over remdesivir — along with cross-family activity against Marburg virus.
Key figures
- Ic50 ebola zaire
- low-micromolar (numeric value not stated in release text)
- Potency vs remdesivir
- 7-fold improvement
- Prv recent transaction range
- $100 million to $180 million
- Potency vs pan coronavirus lead
- >5-fold improvement
- Filovirus historical mortality range
- 40% to 90%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.